India's Piramal Enterprises says gets U.S. nod for new drug trials
Aug 6 (Reuters) - India's Piramal Enterprises Ltd said it has received U.S. regulatory approval to initiate phase I clinical trials for its new drug indicated for lowering lipid and diabetes treatment.
The P7435 molecule has shown significant reduction in triglycerides, blood glucose and insulin levels in pre-clinical studies, the company said in a statement on Tuesday. Its phase I trials will start soon in the United States, it said.
- Malaysia says no evidence missing plane flew hours after losing contact |
- Missing jet may have strayed to west, Malaysia military says |
- White House tried to mediate dispute between Senate, CIA panel: source
- Rescuers seek survivors after NY building collapse; seven dead
- UPDATE 1-U.S. investigators suspect missing Malaysian plane flew for hours -WSJ